Bioasis Technologies said last week that it has entered into its second collaborative research agreement in the last month with the University of British Columbia around p97, a biomarker for Alzheimer's disease.

Under the most recent agreement, researchers from UBC and Bioasis will investigate the use of p97 as a delivery system to transport Alzheimer's compounds across the blood-brain barrier, based on evidence that p97 can shuttle anti-cancer drugs into the brain to treat malignant brain tumors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.

Nov
09
Sponsored by
NuGEN

This webinar will discuss the role of a newly discovered, brain-enriched form of non-CpG DNA methylation in neural development and disease.